Bristol-Myers Squibb Aktie

53,90USD -2,06USD -3,68%
Bristol-Myers Squibb für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 850501 / ISIN: US1101221083
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Personal

2020 2021 2022 2023 2024
Personal am Ende des Jahres 30 250 32 200 34 300 34 100 34 100
Umsatz pro Mitarbeiter in Mio. EUR 1,41 1,44 1,35 1,32 1,42

Bilanz (in Mio. USD) - Aktiva

2020 2021 2022 2023 2024
Summe Umlaufvermögen 30 192 33 262 27 273 31 770 29 780
Summe Anlagevermögen 88 289 76 052 69 547 63 389 62 823
Summe Aktiva 118 481 109 314 96 820 95 159 92 603

Bilanz (in Mio. USD) - Passiva

2020 2021 2022 2023 2024
Summe Fremdkapital 80 599 73 308 65 702 65 674 76 215
Summe Eigenkapital 37 882 36 006 31 118 29 485 16 388
Summe Passiva 118 481 109 314 96 820 95 159 92 603

Adresse

Route 206 & Province Line Road, 08543 Princeton
Telefon +1 (609) 252-4621
Internet http://www.bms.com

Management

Abed Al-Nasser Odeh
Manager
Adam Lenkowsky
Chief Commercialization Officer & Executive VP
Amanda Poole
Chief Human Resources Officer & Executive VP
Amy Fallone
Secretary
Cari Gallman
Executive Vice President-Corporate Affairs
Catalina Vargas
Chief Of Staff
Christopher S. Boerner
Chairman & Chief Executive Officer
David V. Elkins
Chief Financial Officer & Executive Vice President
Deepak L. Bhatt
Independent Director
Derica W. Rice
Independent Director
Estelle Vester-Blokland
Senior VP-Global Medical Affairs
Frank Incontrera
Director-Global Energy Services
Greg Meyers
Chief Digital & Technology Officer
Julia A. Haller
Independent Director
Karen H. Vousden
Independent Director
Kimberly McCutcheon Jablonski
Chief Compliance & Ethics Officer
Manuel Hidalgo Medina
Independent Director
Maria V. Lopez Bresnahan
Vice President
Mark Rolfe
Senior Vice President
Michael R. McMullen
Independent Director
Paula A. Price
Independent Director
Peter J. Arduini
Independent Director
Phil Holzer
Chief Accounting Officer, Senior VP & Controller
Phyllis R. Yale
Independent Director
Robert M. Plenge
Chief Research Officer, Head-Research & EVP
Samit Hirawat
Chief Medical Officer & EVP-Drug Development
Sandra Leung
Executive Vice President & General Counsel
Teresa M. Foy
Senior VP-Immuno Oncology & Cell Therapy
Theodore Rapp Samuels
Lead Independent Director
William Perhacs
Director-Global Energy & Sustainability Services